menu
    • menu
    [{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2015","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Integra LifeSciences \/ Undisclosed"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integrium","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"DSC127","moa":"peptides","graph1":"Podiatry","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integrium","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integrium"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integra LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Dehydrated Human Amnion\/Chorion Membrane","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integra LifeSciences","highestDevelopmentStatusID":"10","companyTruncated":"Integra LifeSciences \/ Integra LifeSciences"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integra LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Dehydrated Human Amnion\/Chorion Membrane","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integra LifeSciences","highestDevelopmentStatusID":"8","companyTruncated":"Integra LifeSciences \/ Integra LifeSciences"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integra LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Propolis","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integra LifeSciences","highestDevelopmentStatusID":"1","companyTruncated":"Integra LifeSciences \/ Integra LifeSciences"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integra LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Integra Flowable Matrix Collagen","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Integra LifeSciences \/ Integra LifeSciences","highestDevelopmentStatusID":"11","companyTruncated":"Integra LifeSciences \/ Integra LifeSciences"},{"orgOrder":0,"company":"Integra LifeSciences","sponsor":"Integra LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Integra LifeSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integra LifeSciences \/ Integra LifeSciences","highestDevelopmentStatusID":"1","companyTruncated":"Integra LifeSciences \/ Integra LifeSciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Integra LifeSciences

    Menu

    Integra LifeSciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dehydrated Human Amnion/Chorion Membrane

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy

                            Details : Dehydrated Human Amnion/Chorion Membrane is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 03, 2023

                            Lead Product(s) : Dehydrated Human Amnion/Chorion Membrane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dehydrated Human Amnion/Chorion Membrane

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : AdventHealth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy

                            Details : Dehydrated Human Amnion/Chorion Membrane is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 06, 2022

                            Lead Product(s) : Dehydrated Human Amnion/Chorion Membrane

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : AdventHealth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Recipient : The Hawkins Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Steroid Injection vs. BioDRestore for Patients With Knee OA

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 10, 2016

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Recipient : The Hawkins Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MEDIHONEY® Gel Versus Collagenase for Wound Debridement

                            Details : Collagenase is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Ulcer.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            June 26, 2015

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propolis

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : University of Maryland, Baltimore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MediHoney for Radiation Dermatitis

                            Details : MediHoney (Honey) is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Breast Neoplasms.

                            Product Name : MediHoney

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 09, 2014

                            Lead Product(s) : Propolis

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : University of Maryland, Baltimore

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSC127

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diab...

                            Details : DSC127 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 09, 2013

                            Lead Product(s) : DSC127

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSC127

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use

                            Details : DSC127 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 25, 2013

                            Lead Product(s) : DSC127

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSC127

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

                            Details : DSC127 is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 12, 2013

                            Lead Product(s) : DSC127

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Sponsor : Integrium

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Integra LifeSciences

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Integra Flowable Matrix Collagen

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Recipient : Georgetown University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of INTEGRAâ„¢ Flowable Wound Matrix to Manage Diabetic Foot Ulcers

                            Details : Integra Flowable Matrix Collagen is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 21, 2010

                            Lead Product(s) : Integra Flowable Matrix Collagen

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Recipient : Georgetown University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth